Jianing Di, Ph.D.

Vice President, International R&D and Corporate Development

Jianing leads Parabilis Medicines’ International R&D and Corporate Development, bringing a global understanding of pharmaceutical R&D and specializing in a range of indications across disease areas and different stages of clinical development. He most recently served as Head, AsiaPac Project Leader Group at Johnson & Johnson Innovative Medicine R&D, where he led the regional asset development teams in delivering the company’s innovative pipeline as part of the global strategy. His leadership was pivotal in driving China and Japan’s growing contribution to global portfolio delivery, and enabled 10+ accelerated pathway designations and 30+ regulatory approvals by NMPA and MHLW, including some flagship assets such as RYBREVANT^®, DARZALEX^®, TREMFYA^® and SPRAVATO^®. As the China Site Head for J&J Innovative Medicine R&D, Jianing was recognized by industry peers, health authorities and academia, and actively represented the company by working as a member of the Drug Information Association (DIA) China Advisory Committee and R&D-Based Pharmaceutical Association Committee (RDPAC) core team.

Jianing holds a Ph.D. in Mathematics from Boston University and a B.S. in Statistics and Economics from Peking University.